Loading...
•
Jun 30, 2025
LivaNova Q2 2025 Earnings Report
LivaNova reported strong second-quarter 2025 results, with double-digit reported and organic revenue growth, continued operating margin expansion, and raised full-year 2025 guidance.
Key Takeaways
LivaNova delivered a robust second quarter in 2025, achieving $352.5 million in revenue, a 10.7% increase year-over-year. The company reported GAAP diluted EPS of $0.50 and adjusted diluted EPS of $1.05, demonstrating strong financial performance driven by growth in both Cardiopulmonary and Neuromodulation segments. LivaNova also raised its full-year 2025 guidance for revenue, adjusted EPS, and adjusted free cash flow.
Second-quarter revenue increased by 10.7% to $352.5 million, with organic growth of 10.3% compared to the prior-year period.
GAAP diluted earnings per share was $0.50, and adjusted diluted earnings per share was $1.05, showing significant improvement.
Operating income increased to $54.2 million, with adjusted operating income reaching $77.4 million, indicating strong operating margin expansion.
Full-year 2025 guidance was raised for revenue growth, adjusted diluted earnings per share, and adjusted free cash flow, reflecting confidence in continued performance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
LivaNova has raised its full-year 2025 guidance across key financial metrics, reflecting strong performance and positive outlook for the remainder of the year.
Positive Outlook
- Full-year 2025 revenue growth range raised by 200 basis points to 8.0% to 9.0% on a constant-currency basis.
- Organic revenue growth guidance raised to 9.0% to 10.0% for full-year 2025.
- Adjusted diluted earnings per share range raised by $0.10 at midpoint to $3.70 to $3.80.
- Adjusted free cash flow range raised by $5 million at midpoint to $140 million to $160 million.
- Foreign currency is now expected to be a tailwind of approximately 1.0%.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company is unable to predict with reasonable certainty the type and extent of certain items that would impact GAAP measures but not non-GAAP measures.
- Reconciliation of forward-looking non-GAAP financial measures to GAAP measures is impractical due to uncertainty and variability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...